Allotex Inc. is an ophthalmic biologics and device company developing new therapeutic solutions for the treatment of presbyopia and hyperopia. The therapy is accomplished through tissue addition technology that uses precisely-shaped human corneal allografts to create what is essentially a permanent, living contact lens or lens insert.
Because the first attempt at this type of solution was over 60 years ago, the safety and efficacy of the approach is well-documented.1
Two key factors have thus far prevented this technology from entering the market:
- Difficulties with precise sculpting of the lens, and
- The limited shelf life of allograft tissue
Today, Allotex’s advanced technologies have resolved both issues, and significant published clinical experience validates its solutions.2
Allotex was founded in 2014 by Dr. David Muller, who also founded Summit Technology (the first company to get FDA approval for laser vision correction). More recently Dr. Muller founded Avedro, Inc., a combination drug and device company that has received FDA approval and Orphan Drug Designation for corneal collagen cross-linking.
Dr. Muller was joined at Allotex in 2015 by Prof. Michael Mrochen of Zurich, who brings a long and esteemed track record of ophthalmic device development, particularly in the area of refractive surgery.
- Corneal transplantation. Retrieved from https://en.wikipedia.org/wiki/Corneal_transplantation#History
- Sun L, Yao P, Li M, Shen Y, Zhao J, Zhou X. The safety and predictability of implanting autologous lenticule obtained by SMILE for hyperopia. J Refract Surg. 2015 Jun;31(6):374-9